Several VDAC1-targeting compounds, such as VBIT-4, VBIT-12, resveratrol, and olesoxime, have demonstrated neuroprotective effects by restoring mitochondrial function, reducing ROS production, and inhibiting pathogenic protein interactions in preclinical models of AD, PD, and ALS. Here, VDAC1 is linked to amyotrophic lateral sclerosis.